Global health care leader Merck (NYSE: MRK) acquired IOmet, a Edinburgh, UK-based drug discovery company.
The financial terms of the acquisition were not disclosed.
Led by Alan Wise, Ph.D., CEO, IOmet focuses on the development of innovative medicines for the treatment of cancer, with a particular emphasis on the fields of cancer immunotherapy and cancer metabolism.
Under terms of the agreement, Merck, through a subsidiary, will acquire IOmet, including its comprehensive pre-clinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors.
IOmet will become a wholly owned subsidiary of Merck.
FinSMEs
12/01/2016